Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Cited by 5 publications
References 0 publications
early tumor mass efficiently, but a single surgical approach seems incompetent for advanced tumor tissues with serious distant metastasis. Surgery cannot completely remove all primary and metastatic tumor cells, thereby generating a high recurrence risk. [2] High-energy radioactive rays are utilized to destroy DNA and protein structures and inhibit there functions in these exposed tumor cells. However, it should be noted that this local irradiationtriggered therapy modality does not distinguish cancer from other tissues, which could induce fatal destruction in circumambient normal tissues. Immunotherapy is an emerging modality that relies on the human immune system and provides a robust defense against advanced and metastatic tumors. [3] Immune checkpoint blockade (ICB) therapy, for example, promotes a systemic immune response that suppresses tumor growth and recurrence by blocking the overexpressed programmed cell death ligand 1 (PD-L1) [4] and CD47 [5] in tumor cells, or cytotoxic T lymphocyte (CTL) associated antigen 4 (CTLA-4) in T cells. [6] Several ICB antibodies, such as pembrolizumab and nivolumab, have been approved by the Food and Drug Administration of the USA (FDA) to treat metastatic colorectal cancer (CRC). [7] Unfortunately, clinical trials revealed that only a fraction of patients with clinical cancer respond to this emerging immunotherapy [8] although this poor efficiency is mainly ascribed to insufficient T cell infiltration [9] and undesirable immunosuppressive microenvironments. [10] Compared to surgery, radiotherapy, and immunotherapy, chemotherapy is preferable as monotherapy or synergetic therapy with the above modalities for cancer treatment. In general, current chemotherapeutic formulations are categorized as solutions and nanoformulations. For example, chemotherapeutic solutions such as Taxel and Doxil are used clinically, but the undesirable selectivity and serious toxicity significantly hinder further application. Compared to solutions, nanoformulations exhibit increased drug accumulation in tumor tissue due to the enhanced permeability and retention (EPR) effect. Specifically, paclitaxel (PTX)-derived Nanoxel shows a higher tumor regression profile than Taxol solution, with improved safety. [11] In addition to EPR-mediated passive accumulation, a liganddirected targeting strategy is also employed in developing nanoparticle (NP) delivery systems as this enables specific ligand-receptor interactions for NP accumulation. [12] To date, numerous tumor microenvironment-sensitive deshielding nanosystems have been fabricated to realize stealth-targeting Nanoparticulate drug delivery systems (nano-DDSs) are required to reliably arrive and persistently reside at the tumor site with minimal off-target side effects for clinical theranostics. However, due to the complicated environment and high interstitial pressure in tumor tissue, they can return to the bloodstream and cause secondary side effects in normal organs. Recently, a number of nanogatekeepers have been engineered via structure-transf...
early tumor mass efficiently, but a single surgical approach seems incompetent for advanced tumor tissues with serious distant metastasis. Surgery cannot completely remove all primary and metastatic tumor cells, thereby generating a high recurrence risk. [2] High-energy radioactive rays are utilized to destroy DNA and protein structures and inhibit there functions in these exposed tumor cells. However, it should be noted that this local irradiationtriggered therapy modality does not distinguish cancer from other tissues, which could induce fatal destruction in circumambient normal tissues. Immunotherapy is an emerging modality that relies on the human immune system and provides a robust defense against advanced and metastatic tumors. [3] Immune checkpoint blockade (ICB) therapy, for example, promotes a systemic immune response that suppresses tumor growth and recurrence by blocking the overexpressed programmed cell death ligand 1 (PD-L1) [4] and CD47 [5] in tumor cells, or cytotoxic T lymphocyte (CTL) associated antigen 4 (CTLA-4) in T cells. [6] Several ICB antibodies, such as pembrolizumab and nivolumab, have been approved by the Food and Drug Administration of the USA (FDA) to treat metastatic colorectal cancer (CRC). [7] Unfortunately, clinical trials revealed that only a fraction of patients with clinical cancer respond to this emerging immunotherapy [8] although this poor efficiency is mainly ascribed to insufficient T cell infiltration [9] and undesirable immunosuppressive microenvironments. [10] Compared to surgery, radiotherapy, and immunotherapy, chemotherapy is preferable as monotherapy or synergetic therapy with the above modalities for cancer treatment. In general, current chemotherapeutic formulations are categorized as solutions and nanoformulations. For example, chemotherapeutic solutions such as Taxel and Doxil are used clinically, but the undesirable selectivity and serious toxicity significantly hinder further application. Compared to solutions, nanoformulations exhibit increased drug accumulation in tumor tissue due to the enhanced permeability and retention (EPR) effect. Specifically, paclitaxel (PTX)-derived Nanoxel shows a higher tumor regression profile than Taxol solution, with improved safety. [11] In addition to EPR-mediated passive accumulation, a liganddirected targeting strategy is also employed in developing nanoparticle (NP) delivery systems as this enables specific ligand-receptor interactions for NP accumulation. [12] To date, numerous tumor microenvironment-sensitive deshielding nanosystems have been fabricated to realize stealth-targeting Nanoparticulate drug delivery systems (nano-DDSs) are required to reliably arrive and persistently reside at the tumor site with minimal off-target side effects for clinical theranostics. However, due to the complicated environment and high interstitial pressure in tumor tissue, they can return to the bloodstream and cause secondary side effects in normal organs. Recently, a number of nanogatekeepers have been engineered via structure-transf...
Many forms of intervention, across different domains, have the surprising effect of widening preexisting gaps between disadvantaged youth and their advantaged counterparts--if such interventions are made available to all students, not just to the disadvantaged. Whether this widening of gaps is incongruent with American interests and values requires an awareness of this gap-widening potential when interventions are universalized and a national policy that addresses the psychological, political, economic, and moral dimensions of elevating the top students--tomorrow's business and science leaders--and/or elevating the bottom students to redress past inequalities and reduce the future costs associated with them. This article is a first step in bringing this dilemma to the attention of scholars and policymakers and prodding a national discussion.
A meta-analysis of 82 recidivism studies (1,620 findings from 29,450 sexual offenders) identified deviant sexual preferences and antisocial orientation as the major predictors of sexual recidivism for both adult and adolescent sexual offenders. Antisocial orientation was the major predictor of violent recidivism and general (any) recidivism. The review also identified some dynamic risk factors that have the potential of being useful treatment targets (e.g., sexual preoccupations, general self-regulation problems). Many of the variables commonly addressed in sex offender treatment programs (e.g., psychological distress, denial of sex crime, victim empathy, stated motivation for treatment) had little or no relationship with sexual or violent recidivism.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
Contact Info
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Product
Resources
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.
